Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

April 10, 2022

Olivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.

April 10, 2022

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.

April 01, 2022

For Dawn Hershman, MD, MS, research and medicine are art forms that she uses to uplift and inspire every day.

March 16, 2022

Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.

December 02, 2021

Nasser Khaled Altorki, MD, provides insight on the results of the IMpower010 trial as well as post hoc analyses from the trial and what they signal for the remainder of this patient population.

November 08, 2021

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.

October 27, 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss the latest findings in small cell lung cancer based on studies that were presented during the 2021 ESMO Congress, 2021 World Conference on Lung Cancer, and 2021 ASCO Annual Meeting.

October 27, 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

October 27, 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, highlight results with immunotherapy in the neoadjuvant and stage IV setting in lung cancer that were presented at the 2021 World Conference on Lung Cancer and the 2021 ESMO Congress.

October 27, 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss breakthroughs in adjuvant immunotherapy in lung cancer from data presented at the 2021 ESMO Congress and 2021 World Conference on Lung Cancer.

October 26, 2021

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

September 30, 2021

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

August 23, 2021

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

August 16, 2021

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

August 16, 2021

Sacituzumab govitecan-hziy, a Trop-2directed antibody-drug conjugate with an SN-38 payload, has carved out a role in the treatment landscape for patients with locally advanced or metastatic urothelial cancer following accelerated approval by the FDA.

August 02, 2021

Gail J. Roboz, MD, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients with acute myeloid leukemia.

July 22, 2021

Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.

July 15, 2021

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

July 08, 2021

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

July 07, 2021

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.